Page 4 - Multiple Ascending Dose News Today

STOCKHOLM, SE / ACCESSWIRE / April 21, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes to those statements included... | March 31, 2022

Artl_10kt.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... | March 21, 2022

STOCKHOLM, SWEDEN / ACCESSWIRE / March 15, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule

Pipe-307 demonstrated linear pharmacokinetic (PK) data consistent with pre-clinical modelling and was generally well tolerated.

AlzeCure presents new clinical data with ACD856 at Alzheimer's conferenceAlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain,...

STOCKHOLM, SWEDEN / ACCESSWIRE / March 8, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates

PRESS RELEASE February 24, 2022 Three Months Ended December 31, 2021 (2020) Revenue was SEK 2.9 M (1.6 M)Operating loss was SEK -125.7 M (-68.6 M)Net loss was SEK -129.9 M (-44.4 M)Basic

Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant Dosing of Inhaled Niclosamide Estimated to Produce Concentrations in Excess of...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.